DefEYE Inc.has launched as an independent ophthalmic biologics company following its transition as a subsidiary of Verséa Health, Inc. The company is focused on advancing eye care through decellularized human placenta-derived biologics, and its portfolio is designed to support both clinical and surgical applications in ocular disease management, according to a press release.

DefEYE is led by Chief Executive Officer Rob Sambursky, MD, a Wills Eye–trained corneal specialist and entrepreneur who has experience in both diagnostic and therapeutic platforms.

DefEYE has also secured exclusive commercial rights to the Biovance franchise, which includes Biovance 3L ocular, among other amniotic basement membrane products. Biovance 3L ocular features a trilayer architecture that has a preserved epithelial basement membrane and intact extracellular matrix.

DefEYE will present its portfolio at AAOpt in Boston (booth #710). For more details, visit www.defeye.com.OM